

Use of Faricimab ▼ (Vabysmo) in



▼ This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions and may do so via the <https://medinfo.roche.com/> website

Disclosures

- Financial disclosure
- The speaker has received consultant fees from Roche
- The speaker has received a fee from Roche to attend a meeting (Euretina)

Vabysmo in

- First injections in January 2023
- Since then we have given 415 injections (31.8.2023)
- Indications: wAMD, DME
- Couple of treatment-naïve wAMD-patients. Mostly as a second line treatment and in 3L after aflibercept
- Overall we are very satisfied with the drug

Vabysmo


- Roche has no influence on the selection of the cases.

- Treatment start with Vabysmo (loading doses): The recommended dose is 6 mg (0.05 mL solution) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses.

Case 1, treatment naive wAMD

- 82 y.o. male
- Left eye AMD -> vision had deteriorated below 0,1 (decimal)
- 12/2022 patient experienced deterioration in his right eye but did not seek help from an ophthalmologist until 4/2023
- Was given a single injection of faricimab on the day of visit, vision was 0,1

Case 1, treatment naive wAMD



Vabysmo

After 4 weeks

2. inj. after 13 weeks

4 weeks after 2. inj.

Vision 0,1


Vision improved 70,15

Case 2, switch from aflibercept/brolucizumab

- Female, wAMD in both eyes

- Previously treated with multiple injections with 1L treatment option, aflibercept ja brolucizumab injections
- Was given Vabysmo-injections to both eyes in February 2023


Case 2, switch from aflibercept/brolucizumab



Left image: OD, was given aflibercept 4 weeks earlier

Right image: the same eye 4 weeks after Vabysmo

VA: improvement from 0,5 to 0,63



Left image: OS, was given brolucizumab 4 weeks earlier

Right image: the same eye 4 weeks after Vabysmo


VA: improvement from 0,25 to 0,4

Both eyes after Vabysmo: stayed dry for about 13-14 weeks

Case 3, PCV

- 77 yo. Female
- PCV in right eye
- 1L treatment option x3, aflibercept x 16

Case 3, PCV



Massive PCV, was given Vabysmo x2 on a 4 week interval


VA gain from 0,25 to 0,63

Case 4, DME and subretinal haemorrhage

- 64 yo. Female

- DME
- Developed a subretinal haemorrhage, was old at the time of diagnosis so no VR-surgery
- Was given 1L treatment option x3, insufficient result
- Was given Vabysmo x3 with a 4 week interval

Case 4, DME and subretinal haemorrhage




2/23 ⑦ 1L tretment x3, situation 5/23 and finally after 3
Vabysmos



VA gain from 0,3 to 0,63

Case 5, DME

- 67 yo. Male
- DME in right eye
- Multiple injections including 1L treatment option, aflibercept, triamcinolone, dexamethasone-implant with insufficient results
- Vabysmo 6/23 x2 with a 4 week interval



Case 5, DME



Anatomical improvement after 2 Vabysmos (4 week interval)

Vision drop from 0,32 to 0,25 BUT his cataract (due to i.v. corticosteroids) is maturing fast (myopic shift) which probably explains the drop in vision

Cataract surgery is planned to be operated in between Vabysmo injections, injections are continued with a 4 week interval

Summary

- Vabysmo works well as 1L treatment option
- We have had good results also as a 2L and even as 3L option
- In some cases the results come after two to three injections, probably due to ang2-inhibition taking a bit longer to achieve, so take your time and load if necessary